Tag: Roche

A letter from Roche

Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership Director, Mai-Lise Nguyen, write about the company and their philosophy on working with the HD patient community. On behalf of the Roche HD team Nguyen writes: – Since taking over development of RG6042 from Ionis…
Read more

Amazing news – drug seems to improve symptoms

Yesterday Ionis Pharmaceutical presented new data from their Huntingtin lowering trial, IONIS-HTTRx. The data demonstrates a relationship between reduction of the disease-causing  Huntingtin protein and improved symptoms for people with early stage Huntington’s Disease. After 3 months of treatment, the patients seems to benefit from the drug – now known as RG6042. This is very…
Read more

Update message from the Roche team

On her way to board a flight to Los Angeles Mai-Lise Nguyen, Patient Partnership Director at Roche, sent an update letter to all of us who are impatiently waiting for news about the upcoming trial.  Well, there are no concrete timeline presented yet, but the letter reassures that the preparations are in progress. Ms Nguyen…
Read more